Inventia’s Generic Fanapt Unlikely to Hit Market Soon

It’s unlikely a cheaper, generic version of Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt will hit the market anytime soon.

The Food and Drug Administration green-lighted Indian company Inventia Healthcare Pvt Ltd.'s generic version Dec. 5, but no Fanapt generic has been launched. Now we know why.

Vanda and Inventia entered into a confidential agreement regarding any potential launch date for Inventia’s generic iloperidone product, Vanda said in a Dec. 19 securities filing. The agreement is likely critical to Vanda because Fanapt (iloperidone) makes up half of Vanda’s revenues and the company.

Other ...